Sequence Variants of NAT1 and NAT2 and Other Xenometabolic Genes and Risk of Lung and Aerodigestive Tract Cancers in Central Europe
Authors:
- James D. McKayJMJames D. McKay
- Mia HashibeMHMia Hashibe
- Rayjean J. HungRHRayjean J. Hung
- Valerie GaborieauVGValerie Gaborieau
- David ZaridzeDZDavid Zaridze
- Jolanta LissowskaJLJolanta Lissowska
- Peter RudnaiPRPeter Rudnai
- Eleonora FabianovaEFEleonora Fabianova
- Dana MatesDMDana Mates
- Lenka ForetovaLFLenka Foretova
Open Access
- 1 January 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (1) , 141-147
Abstract
Tobacco smoke contains an extensive cocktail of highly carcinogenic chemicals. Individuals with a slower elimination rate of the chemicals in tobacco smoke may have increased exposure to their carcinogenic properties compared with those with a faster rate. Polymorphisms that alter the function of the genes involved in the activation or the detoxification of the chemical carcinogens in tobacco smoke can potentially influence an individual's risk of developing a tobacco-related cancer. To test this hypothesis, we have genotyped polymorphisms in 16 genes involved in metabolism of chemical carcinogens in a Central and Eastern European case-control study comprising 2,250 lung cases, 811 upper aerodigestive cancer (UADT) cases, and 2,704 controls. The N-acetyltransferase (NAT) genes were the most implicated in risk, with the NAT1*10 haplotype showing an inverse association in lung cancer, in both heterozygote carriers [odds ratio (OR), 0.81; 95% confidence interval (95% CI), 0.70-0.93] and homozygote carriers (OR, 0.70; 95% CI, 0.48-1.01), suggesting a genotype dose response (P < 0.001). In UADT cancer, a similar inverse association was noted in NAT1*10 although only in heterozygotes (OR, 0.78; 95%CI, 0.65-0.95). In NAT2, when considering the individuals inferred acetylator phenotypes based on their NAT2 diplotype, “slow” acetylators compared with intermediate or fast acetylators showed no association with risk. None of the other 14 genes provided robust evidence of an association for either lung or UADT cancer. We therefore conclude that, of the genetic variation studied, NAT1 gene was the most likely candidate to influence the risk of developing a tobacco-related cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(1):141–7)Keywords
This publication has 17 references indexed in Scilit:
- A Bayesian Measure of the Probability of False Discovery in Genetic Epidemiology StudiesThe American Journal of Human Genetics, 2007
- Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neckHead & Neck, 2007
- Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genesCarcinogenesis, 2007
- Cigarette Smoking, N -Acetyltransferase Genes and the Risk of Advanced Colorectal AdenomaPharmacogenomics, 2006
- Lack of Associations among Cancer and Albumin Adducts, ras p21 Oncoprotein Levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a Nested Case-Control Study of Lung Cancer within the Physicians' Health StudyCancer Epidemiology, Biomarkers & Prevention, 2006
- N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer riskOncogene, 2006
- NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesThe Lancet, 2005
- Occupational Exposure to Vinyl Chloride, Acrylonitrile and Styrene and Lung Cancer Risk (Europe)Cancer Causes & Control, 2004
- Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibilityPharmacogenetics, 2001
- N-acetyltranferase NAT1 and NAT2 genotypes and lung cancer riskPharmacogenetics, 1998